Nektar Therapeutics (NKTR) Tops Q2 EPS by 77c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/15/2026
- Nasdaq ends sharply lower as hot inflation data stirs rate-hike worries
- Oil prices gain on attacks in Saudi Arabia, Iran's new tactics to target tankers
- U.S. consumer prices rise by 3.7% year-on-year in September
- Bank of America stock falls on earnings miss
- Netflix cuts 1,000 jobs as streaming giant seeks to boost engagement
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $36.89 --0%
Revenue Growth %: -13.0%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
FMCB, BANF, LOOP, More
Revenue Growth %: -13.0%
Financial Fact:
License, collaboration and other: 8.37M
Today's EPS Names:
FMCB, BANF, LOOP, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($1.23), $0.77 better than the analyst estimate of ($2.00). Revenue for the quarter came in at $10.13 million versus the consensus estimate of $10.38 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DigitalOcean (DOCN) Reiterated at Market Outperform by Citizens Post Open Intelligence Summit
- Mizuho Upgrades Array Technologies (ARRY) to Outperform
- Needham Starts CAMP4 Therapeutics Corp (CAMP) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
